|
Items in cart [0] |
Questions? Call 888-624-8373 |
PAPERBACK + PDF PAPERBACK PDF BOOK PDF CHAPTERS Free Resources |
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Strategy Is Needed for Cultural Change at FAA. GAO/RCED-96-159. Washington, DC: GAO. GAO. 2002. Food and Drug Administration: Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities. GAO-02-958. Washington, DC: GAO. GAO. 2003. Air Traffic Control FAA’s Modernization Efforts—Past, Present, and Future. Statement of Gerald L. Dillingham, Director, Physical Infrastructure Issues. GAO-04-227T. Washington, DC: GAO. GAO. 2005. Decision Process to Deny Initial Application for Over-the-Counter Marketing of Emergency Contraceptive Drug Plan B Was Unusual. GAO-06-109. Washington, DC: GAO. GAO. 2006. Drug Safety: Improvement Needed in FDA’s Postmarket Decision-Making and Oversight Process. GAO-06-402. Washington, DC: GAO. Grassley C. 2005. A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. S.930. 109th Cong., 1st Sess. April 27, 2005. Grassley C, Baucus M, Graham D, Singh G, Psaty B, Kweder S, Gilmartin R. 2004. FDA, Merck and Vioxx: Putting Patient Safety First? Statements at the November 18, 2004 hearing before the United States Senate Committee on Finance, United States Senate. Harris G. 2004. At F.D.A., Strong Drug Ties and Less Monitoring. [Online]. Available: http://www.nytimes.com/2004/12/06/health/06fda.html [accessed December 6, 2004]. Harris G. 2005. F.D.A. Moves Toward More Openness with the Public. [Online]. Available: http://query.nytimes.com/gst/fullpage.html?sec=health&res=9A0CEFDE1E3AF933A15751C0A9639C8B63 [accessed July 17, 2006]. Harris G. 2006a. Halt Is Urged for Trials of Antibiotic in Children. [Online]. Available: http://www.nytimes.com/2006/06/08/science/08drug.html [accessed June 8, 2006]. Harris G. 2006b. Approval of Antibiotic Worried Safety Officials. [Online]. Available: http://www.nytimes.com/2006/07/19/health/19fda.html [accessed July 21, 2006]. Heifetz RA, Laurie DL. 1998. The work of leadership. Harvard Business Review on leadership. Harvard Business School Press. Pp. 171-199. Henderson D. 2005 (December 6). Whistleblower’s case casts further shadows on FDA’s ties with drug makers. The Boston Globe. Hendrick B. 2006 (July 21). Respiratory drugs’ safety questioned. The Atlanta Journal-Constitution. p. 8A. Hensley S, Davies P, Martinez B. 2005. Vioxx Verdict Stokes Backlash That Hit FDA, Manufacturers. [Online]. Available at: http://online.wsj.com/article/0,,SB112467370587619279-email,00.html [accessed October 10, 2005]. House of Commons Health Committee. 2005a. The Influence of the Pharmaceutical Industry Fourth Report of Session 2004–05 Volume I. London: The Stationery Office Limited. House of Commons Health Committee. 2005b. The Influence of the Pharmaceutical Industry Fourth Report of Session 2004–05 Volume II. London: The Stationery Office Limited. IOM (Institute of Medicine). 2005 (July 20). Transcript, Meeting Two of the IOM Committee on the Assessment of the US Drug Safety System. Washington, DC: IOM. Johnson L, US PIRG (United States Public Interest Research Group). 2005 (July 19). Presentation at Meeting Two of the IOM Committee on the Assessment of the US Drug Safety System. Washington, DC: Institute of Medicine. Kaiser Family Foundation. 2005. Kaiser HealthPoll Report Views on Prescription Drugs and the Pharmaceutical Industry. [Online]. Available: http://www.kff.org/healthpollreport/feb_2005/upload/full_report.pdf [accessed September 22, 2005]. Kaufman. 2004a (December 19). FDA’s reliance on unconfirmed chiefs is faulted. Washington Post, p. A01. Kaufman M. 2004b. White House Defends FDA as Drug Safety Debate Looms. [Online]. Available: http://www.washingtonpost.com/wp-dyn/articles/A11900-2004Dec19.html [accessed December 20, 2004].
|
|
|||||||||||||||
